Akero Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch AKRO and buy or sell other stocks, ETFs, and their options commission-free!About AKRO
Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body.
CEOAndrew Cheng, MD, PhD
CEOAndrew Cheng, MD, PhD
Employees63
Employees63
HeadquartersSouth San Francisco, California
HeadquartersSouth San Francisco, California
Founded2017
Founded2017
Employees63
Employees63
AKRO Key Statistics
Market cap4.38B
Market cap4.38B
Price-Earnings ratio-14.58
Price-Earnings ratio-14.58
Dividend yield—
Dividend yield—
Average volume2.00M
Average volume2.00M
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$58.40
52 Week high$58.40
52 Week low$21.34
52 Week low$21.34
Stock Snapshot
Akero Therapeutics(AKRO) stock is priced at $54.65, giving the company a market capitalization of 4.38B. It carries a P/E multiple of -14.58.
On 2026-01-08, Akero Therapeutics(AKRO) stock opened at —, reached a high of —, and a low of —.
Akero Therapeutics(AKRO) shares are trading with a volume of 0, against a daily average of 2M.
During the past year, Akero Therapeutics(AKRO) stock moved between $21.34 at its lowest and $58.40 at its peak.
During the past year, Akero Therapeutics(AKRO) stock moved between $21.34 at its lowest and $58.40 at its peak.
People also own
Based on the portfolios of people who own AKRO. This list is generated using Robinhood data, and it’s not a recommendation.